Track topics on Twitter Track topics that are important to you
Will CART cell therapies shape the treatment of blood cancers in the next decade?
AntiCD19 CART cell therapies have demonstrated unprecedented response rates across patient subgroups of acute lymphocytic leukaemia ALL and nonHodgkin lymphoma NHL with high unmet needs. How will the impressive efficacy and safety of these therapies pan out in the longterm? Key opinion leaders KOLs explore the clinical challenges and opportunities that face these exciting treatments across multiple haematological cancer settings. Experts discuss the logistical, pricing, reimbursement and market access PRMA hurdles facing these novel therapies and how they can be overcome. Learn how KOLs see the future CART therapy market evolving, and how they expect developers to successfully differentiate their CART therapies in KOL Insight: CART cell Therapy in Haematological Malignancy. Eight US KOLs also provide their candid views on the potential for nextgeneration approaches, allogeneic CART therapies and other novel strategies
Take a tour of the report now:
The response is impressive enough that I see [CART therapies] being around in 10 to 15 years. Exactly where to use them and when to use them is still unknown. I see them being used for lymphoma, ALL, and in multiple myeloma, we'll have to see.US Key Opinion Leader
The responses for ALL are unprecedented. Somewhere between 80 to 90 percent of patients achieve a complete remission, and that's across different CAR programmes, and so it really does tell you it's a feature of the technology and not some secret at one company or one institution over another.US Key Opinion Leader
A report based on expert knowledge
Key Opinion Leaders Interviewed for This Report
North American KOLs
Sample of therapies covered
Sample of KOLs interviewed
KOLs from North America
Money Back Guarantee
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.NEXT ARTICLE